{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:56:36Z","timestamp":1792112196775,"version":"4.4.0"},"reference-count":226,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003991, 81973587, 81973734"],"award-info":[{"award-number":["82003991, 81973587, 81973734"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immunotherapy has been recognized as an effective and important therapeutic modality for multiple types of cancer. Nevertheless, it has been increasing recognized that clinical benefits of immunotherapy are less than expected as evidenced by the fact that only a small population of cancer patients respond favorably to immunotherapy. The structurally and functionally abnormal tumor vasculature is a hallmark of most solid tumors and contributes to an immunosuppressive microenvironment, which poses a major challenge to immunotherapy. In turn, multiple immune cell subsets have profound consequences on promoting neovascularization. Vascular normalization, a promising anti-angiogenic strategy, can enhance vascular perfusion and promote the infiltration of immune effector cells into tumors <jats:italic>via<\/jats:italic> correcting aberrant tumor blood vessels, resulting in the potentiation of immunotherapy. More interestingly, immunotherapies are prone to boost the efficacy of various anti-angiogenic therapies and\/or promote the morphological and functional alterations in tumor vasculature. Therefore, immune reprograming and vascular normalization appear to be reciprocally regulated. In this review, we mainly summarize how tumor vasculature propels an immunosuppressive phenotype and how innate and adaptive immune cells modulate angiogenesis during tumor progression. We further highlight recent advances of anti-angiogenic immunotherapies in preclinical and clinical settings to solidify the concept that targeting both tumor blood vessels and immune suppressive cells provides an efficacious approach for the treatment of cancer.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1035323","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T06:11:41Z","timestamp":1668060701000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":50,"title":["Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade"],"prefix":"10.3389","volume":"13","author":[{"given":"Weiwei","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueke","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiliang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001460","article-title":"Rethinking immune checkpoint blockade: 'Beyond the T cell'","volume":"9","author":"Liu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abj8825","article-title":"Immune checkpoint blockade sensitivity and progression-free survival associates with baseline Cd8(+) T cell clone size and cytotoxicity","volume":"6","author":"Watson","year":"2021","journal-title":"Sci Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00561","article-title":"Pd-1 and pd-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (Keynote-224): A non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (Checkmate 040): An open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw7875","article-title":"Vascular regulation of antitumor immunity","volume":"365","author":"Munn","year":"2019","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-3896","article-title":"Claudin-12 deficiency inhibits tumor growth by impairing transendothelial migration of myeloid-derived suppressor cells","volume":"82","author":"Cao","year":"2022","journal-title":"Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00527","article-title":"Contribution to tumor angiogenesis from innate immune cells within the tumor microenvironment: Implications for immunotherapy","volume":"9","author":"Albini","year":"2018","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2017.145","article-title":"Improving immune-vascular crosstalk for cancer immunotherapy","volume":"18","author":"Huang","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The intersection between tumor angiogenesis and immune suppression","volume":"25","author":"Rahma","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10456-017-9552-y","article-title":"Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy","volume":"20","author":"Ramjiawan","year":"2017","journal-title":"Angiogenesis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.316851","article-title":"Basic and therapeutic aspects of angiogenesis updated","volume":"127","author":"Eelen","year":"2020","journal-title":"Circ Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.01.021","article-title":"Vegf in signaling and disease: Beyond discovery and development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-4354","article-title":"Vascular normalization as an emerging strategy to enhance cancer immunotherapy","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12019","article-title":"Vegfa and tumour angiogenesis","volume":"273","author":"Claesson-Welsh","year":"2013","journal-title":"J Intern Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.3390\/ijms18112291","article-title":"Synergies of targeting tumor angiogenesis and immune checkpoints in non-small cell lung cancer and renal cell cancer: From basic concepts to clinical reality","volume":"18","author":"Pircher","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2017.12.002","article-title":"Predictive markers of anti-vegf and emerging role of angiogenesis inhibitors as immunotherapeutics","volume":"52","author":"Hegde","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.100954","article-title":"Vegfr1 signaling in retinal angiogenesis and microinflammation","volume":"84","author":"Uemura","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13009","article-title":"Inhibition of fgf-fgfr and vegf-vegfr signalling in cancer treatment","volume":"54","author":"Liu","year":"2021","journal-title":"Cell Prolif"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2021.1947246","article-title":"Selective Fgfr\/Fgf pathway inhibitors: Inhibition strategies, clinical activities, resistance mutations, and future directions","volume":"14","author":"Repetto","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.cytogfr.2021.09.002","article-title":"Fgf\/Fgfr signaling: From lung development to respiratory diseases","volume":"62","author":"Yang","year":"2021","journal-title":"Cytokine Growth Factor Rev"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.3390\/ijms19071875","article-title":"Fgf family: From drug development to clinical application","volume":"19","author":"Hui","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2022.01.113","article-title":"Targeting the Pdgf\/Pdgfr signaling pathway for cancer therapy: A review","volume":"202","author":"Zou","year":"2022","journal-title":"Int J Biol Macromol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.critrevonc.2018.08.002","article-title":"The role of pdgf-B\/Pdgfr-Beta axis in the normal development and carcinogenesis of the breast","volume":"131","author":"Jitariu","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201708253","article-title":"Ang2 inhibitors and Tie2 activators: Potential therapeutics in perioperative treatment of early stage cancer","volume":"13","author":"Khan","year":"2021","journal-title":"EMBO Mol Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3390\/cells8050471","article-title":"Role of angiopoietin-2 in vascular physiology and pathophysiology","volume":"8","author":"Akwii","year":"2019","journal-title":"Cells"},{"key":"B29","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.3390\/cancers13225730","article-title":"Targeting Tie2 in the tumor microenvironment: From angiogenesis to dissemination","volume":"13","author":"Duran","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"8689","DOI":"10.3390\/ijms21228689","article-title":"The angiopoietin-2 and tie pathway as a therapeutic target for enhancing antiangiogenic therapy and immunotherapy in patients with advanced cancer","volume":"21","author":"Leong","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-3-030-47189-7_2","article-title":"Hgf\/C-met signalling in the tumor microenvironment","volume":"1270","author":"Zambelli","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12943-022-01503-1","article-title":"Molecular Mechanism(S) of Regulation(S) of c-Met\/Hgf signaling in head and neck cancer","volume":"21","author":"Raj","year":"2022","journal-title":"Mol Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"7546","DOI":"10.3390\/ijms21207546","article-title":"Hgf\/Met signaling in malignant brain tumors","volume":"21","author":"Mulcahy","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41419-021-03882-7","article-title":"Prrx1 promotes stemness and angiogenesis Via activating tgf-Beta\/Smad pathway and upregulating proangiogenic factors in glioma","volume":"12","author":"Chen","year":"2021","journal-title":"Cell Death Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/jcp.30529","article-title":"Tgf-beta signaling: A recap of smad-independent and smad-dependent pathways","volume":"237","author":"Aashaq","year":"2022","journal-title":"J Cell Physiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2020.11.048","article-title":"Genetic perturbation of ifn-alpha transcriptional modulators in human endothelial cells uncovers pivotal regulators of angiogenesis","volume":"18","author":"Ciccarese","year":"2020","journal-title":"Comput Struct Biotechnol J"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2018.01.039","article-title":"Endothelial cell functions impaired by interferon in vitro: Insights into the molecular mechanism of thrombotic microangiopathy associated with interferon therapy","volume":"163","author":"Jia","year":"2018","journal-title":"Thromb Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.3390\/cells11091502","article-title":"Crocin inhibits angiogenesis and metastasis in colon cancer Via tnf-Alpha\/Nf-Kb\/Vegf pathways","volume":"11","author":"Bakshi","year":"2022","journal-title":"Cells"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01426","article-title":"Il-1 family cytokine regulation of vascular permeability and angiogenesis","volume":"10","author":"Fahey","year":"2019","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1\u201314","DOI":"10.1111\/imm.13486","article-title":"Pathogenetic role and clinical significance of interleukin-1beta in cancer","author":"Malkova","year":"2022","journal-title":"Immunology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108850","article-title":"Interleukin-33 protects mice against hindlimb ischemic injury by enhancing endothelial angiogenesis","volume":"109","author":"Dong","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00334","article-title":"Interleukin-18 amplifies macrophage polarization and morphological alteration, leading to excessive angiogenesis","volume":"9","author":"Kobori","year":"2018","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jot.2019.07.007","article-title":"Genistein inhibits angiogenesis developed during rheumatoid arthritis through the il-6\/Jak2\/Stat3\/Vegf signalling pathway","volume":"22","author":"Cheng","year":"2020","journal-title":"J Orthop Translat"},{"key":"B44","doi-asserted-by":"publisher","first-page":":6858","DOI":"10.3390\/molecules26226858","article-title":"Nifuroxazide mitigates angiogenesis in ehlrich's solid carcinoma: Molecular docking, bioinformatic and experimental studies on inhibition of il-6\/Jak2\/Stat3 signaling","volume":"26","author":"El-Sherbiny","year":"2021","journal-title":"Molecules"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2018.05.004","article-title":"Lifr promotes tumor angiogenesis by up-regulating il-8 levels in colorectal cancer","volume":"1864","author":"Wu","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107692","article-title":"Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression","volume":"219","author":"Fousek","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2015.1062475","article-title":"The potential of fibroblast growth Factor\/Fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis","volume":"19","author":"Ronca","year":"2015","journal-title":"Expert Opin Ther Targets"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14854","article-title":"Vascular reconstitution in the tumor for more effective tumor immunotherapy","volume":"112","author":"Takakura","year":"2021","journal-title":"Cancer Sci"},{"key":"B49","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.canlet.2020.05.015","article-title":"Hypoxia: Turning vessels into vassals of cancer immunotolerance","volume":"487","author":"Schito","year":"2020","journal-title":"Cancer Lett"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-020518-114721","article-title":"Regulation of blood and lymphatic vessels by immune cells in tumors and metastasis","volume":"81","author":"Mazzone","year":"2019","journal-title":"Annu Rev Physiol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"4987","DOI":"10.3390\/cancers13194987","article-title":"Mechanical aspects of angiogenesis","volume":"13","author":"Kretschmer","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvq049","article-title":"Extracellular matrix, inflammation, and the angiogenic response","volume":"86","author":"Arroyo","year":"2010","journal-title":"Cardiovasc Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270819","article-title":"Identification and functional analysis of endothelial tip cell-enriched genes","volume":"116","author":"del Toro","year":"2010","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2010.08.010","article-title":"Dynamics of endothelial cell behavior in sprouting angiogenesis","volume":"22","author":"Eilken","year":"2010","journal-title":"Curr Opin Cell Biol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3390\/biomedicines10020300","article-title":"Cooperation between angiogenesis, vasculogenesis, chemotaxis, and coagulation in breast cancer metastases development: Pathophysiological point of view","volume":"10","author":"Zarychta","year":"2022","journal-title":"Biomedicines"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.153922","article-title":"Vascular mimicry: A potential therapeutic target in breast cancer","volume":"234","author":"Chavoshi","year":"2022","journal-title":"Pathol Res Pract"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.14670\/HH-18-222","article-title":"Intussusceptive angiogenesis and its counterpart intussusceptive lymphangiogenesis","volume":"35","author":"Diaz-Flores","year":"2020","journal-title":"Histol Histopathol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01686-2","article-title":"Vessel Co-option and angiotropic extravascular migratory metastasis: A continuum of tumour growth and spread","volume":"126","author":"Lugassy","year":"2022","journal-title":"Br J Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0181-9","article-title":"Vessel Co-option in cancer","volume":"16","author":"Kuczynski","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-017-9562-9","article-title":"Tumor angiogenesis and vascular normalization: Alternative therapeutic targets","volume":"20","author":"Viallard","year":"2017","journal-title":"Angiogenesis"},{"key":"B61","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1159\/000338278","article-title":"Intussusceptive angiogenesis: A biologically relevant form of angiogenesis","volume":"49","author":"De Spiegelaere","year":"2012","journal-title":"J Vasc Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0985","article-title":"T-Cell and nk-cell infiltration into solid tumors: A key limiting factor for efficacious cancer immunotherapy","volume":"4","author":"Melero","year":"2014","journal-title":"Cancer Discovery"},{"key":"B63","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.coi.2015.01.011","article-title":"Targeting the tumor vasculature to enhance T cell activity","volume":"33","author":"Lanitis","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp Mol Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and pd-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","first-page":"6340","DOI":"10.1038\/ncomms7340","article-title":"The hif-1\/Glial Tim-3 axis controls inflammation-associated brain damage under hypoxia","volume":"6","author":"Koh","year":"2015","journal-title":"Nat Commun"},{"key":"B67","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/ijc.30077","article-title":"Pd-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma","volume":"139","author":"Ruf","year":"2016","journal-title":"Int J Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26410","article-title":"Tumor lactic acidosis suppresses ctl function by inhibition of P38 and Jnk\/C-jun activation","volume":"131","author":"Mendler","year":"2012","journal-title":"Int J Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"8363","DOI":"10.3390\/ijms21218363","article-title":"Lactic acid and an acidic tumor microenvironment suppress anticancer immunity","volume":"21","author":"Wang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1021\/acsbiomaterials.0c01542","article-title":"Microfluidic tumor vasculature model to recapitulate an endothelial immune barrier expressing fasl","volume":"7","author":"Kim","year":"2021","journal-title":"ACS Biomater Sci Eng"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/nature10169","article-title":"Tumour hypoxia promotes tolerance and angiogenesis Via Ccl28 and T(Reg) cells","volume":"475","author":"Facciabene","year":"2011","journal-title":"Nature"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.741305","article-title":"Tumor-associated macrophages and their functional transformation in the hypoxic tumor microenvironment","volume":"12","author":"He","year":"2021","journal-title":"Front Immunol"},{"key":"B74","article-title":"Role of hypoxia in inhibiting dendritic cells by vegf signaling in tumor microenvironments: Mechanism and application","volume":"11","author":"Han","year":"2021","journal-title":"Am J Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3962","article-title":"The tumor microenvironment innately modulates cancer progression","volume":"79","author":"Hinshaw","year":"2019","journal-title":"Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2444","article-title":"The role of myeloid cells in the promotion of tumour angiogenesis","volume":"8","author":"Murdoch","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3581","article-title":"History of myeloid-derived suppressor cells","volume":"13","author":"Talmadge","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B78","article-title":"Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma","volume":"56","author":"Leek","year":"1996","journal-title":"Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.09.008","article-title":"Macrophage metabolism controls tumor blood vessel morphogenesis and metastasis","volume":"24","author":"Wenes","year":"2016","journal-title":"Cell Metab"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188434","article-title":"Targeting tumor-associated macrophages for cancer immunotherapy","volume":"1874","author":"Shu","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2016.3616","article-title":"Neutrophils in cancer development and progression: Roles, mechanisms, and implications (Review)","volume":"49","author":"Zhang","year":"2016","journal-title":"Int J Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3791\/59807","article-title":"Transfer of manipulated tumor-associated neutrophils into tumor-bearing mice to study their angiogenic potential in vivo","author":"Pylaeva","year":"2019","journal-title":"J Vis Exp"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.51","article-title":"Microenvironmental regulation of tumour angiogenesis","volume":"17","author":"De Palma","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B84","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ccell.2016.05.017","article-title":"The multifaceted role of perivascular macrophages in tumors","volume":"30","author":"Lewis","year":"2016","journal-title":"Cancer Cell"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1158\/2326-6066.CIR-15-0313","article-title":"The complex role of neutrophils in tumor angiogenesis and metastasis","volume":"4","author":"Liang","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.06.017","article-title":"Polarization of tumor-associated neutrophil phenotype by tgf-beta: \"N1\" versus \"N2\" tan","volume":"16","author":"Fridlender","year":"2009","journal-title":"Cancer Cell"},{"key":"B88","article-title":"Direct actions of angiopoietin-1 on human endothelium: Evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors","volume":"79","author":"Papapetropoulos","year":"1999","journal-title":"Lab Invest"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.17","article-title":"Tumour immunology: Neutrophils help tumours spread","volume":"16","author":"Bird","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1172\/JCI37223","article-title":"Neutrophils responsive to endogenous ifn-beta regulate tumor angiogenesis and growth in a mouse tumor model","volume":"120","author":"Jablonska","year":"2010","journal-title":"J Clin Invest"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.2174\/156652410791316968","article-title":"Molecular pathways linking inflammation and cancer","volume":"10","author":"Mantovani","year":"2010","journal-title":"Curr Mol Med"},{"key":"B92","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.it.2015.02.006","article-title":"Immune-mediated mechanisms influencing the efficacy of anticancer therapies","volume":"36","author":"Coffelt","year":"2015","journal-title":"Trends Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-016-0820-y","article-title":"Diverse macrophages polarization in tumor microenvironment","volume":"39","author":"Rhee","year":"2016","journal-title":"Arch Pharm Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.10.4153","article-title":"Intracellular pool of vascular endothelial growth factor in human neutrophils","volume":"90","author":"Gaudry","year":"1997","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/35036374","article-title":"Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis","volume":"2","author":"Bergers","year":"2000","journal-title":"Nat Cell Biol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0601807103","article-title":"Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis","volume":"103","author":"Nozawa","year":"2006","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1278","article-title":"Macrophages regulate the angiogenic switch in a mouse model of breast cancer","volume":"66","author":"Lin","year":"2006","journal-title":"Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/nature06348","article-title":"Bv8 regulates myeloid-Cell-Dependent tumour angiogenesis","volume":"450","author":"Shojaei","year":"2007","journal-title":"Nature"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.654877","article-title":"The cancer cell dissemination machinery as an immunosuppressive niche: A new obstacle towards the era of cancer immunotherapy","volume":"12","author":"Asiry","year":"2021","journal-title":"Front Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.2174\/0929867328666210720143721","article-title":"The role of tumor associated macrophages (Tams) in cancer progression, chemoresistance, angiogenesis and metastasis - current status","volume":"28","author":"Dallavalasa","year":"2021","journal-title":"Curr Med Chem"},{"key":"B101","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12929-019-0568-z","article-title":"Tumor-associated macrophages: An accomplice in solid tumor progression","volume":"26","author":"Chen","year":"2019","journal-title":"J BioMed Sci"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191012","article-title":"M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma","volume":"13","author":"Jarosz-Biej","year":"2018","journal-title":"PloS One"},{"key":"B103","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1002\/path.4133","article-title":"Macrophage plasticity and polarization in tissue repair and remodelling","volume":"229","author":"Mantovani","year":"2013","journal-title":"J Pathol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.3390\/cancers13133253","article-title":"New angiogenic regulators produced by tams: Perspective for targeting tumor angiogenesis","volume":"13","author":"Larionova","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.11.024","article-title":"M2 macrophage-derived exosomes promote angiogenesis and growth of pancreatic ductal adenocarcinoma by targeting E2f2","volume":"29","author":"Yang","year":"2021","journal-title":"Mol Ther"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.10.045","article-title":"M2 macrophage-derived exosomes promote lung adenocarcinoma progression by delivering mir-942","volume":"526","author":"Wei","year":"2022","journal-title":"Cancer Lett"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.29184","article-title":"Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer","volume":"15","author":"Reusser","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603240","article-title":"Clodronate-Liposome-Mediated depletion of tumour-associated macrophages: A new and highly effective antiangiogenic therapy approach","volume":"95","author":"Zeisberger","year":"2006","journal-title":"Br J Cancer"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-237412","article-title":"Targeting distinct tumor-infiltrating myeloid cells by inhibiting csf-1 receptor: Combating tumor evasion of antiangiogenic therapy","volume":"115","author":"Priceman","year":"2010","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/nature07445","article-title":"Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis","volume":"456","author":"Stockmann","year":"2008","journal-title":"Nature"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2868","article-title":"Targeting the tumour vasculature: Insights from physiological angiogenesis","volume":"10","author":"Chung","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0666-9","article-title":"Regulatory myeloid cells paralyze T cells through cell-cell transfer of the metabolite methylglyoxal","volume":"21","author":"Baumann","year":"2020","journal-title":"Nat Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.11.038","article-title":"Polymorphonuclear-mdscs facilitate tumor regrowth after radiation by suppressing Cd8(+) T cells","volume":"109","author":"Zhang Md","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B115","article-title":"Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression","volume":"63","author":"Dirkx","year":"2003","journal-title":"Cancer Res"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.03.055","article-title":"Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy","volume":"11","author":"Rivera","year":"2015","journal-title":"Cell Rep"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3159","article-title":"Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of Cd8(+) T cells","volume":"16","author":"Carretero","year":"2015","journal-title":"Nat Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2007.07.006","article-title":"Dendritic cell-endothelial cell cross-talk in angiogenesis","volume":"28","author":"Sozzani","year":"2007","journal-title":"Trends Immunol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1272","article-title":"Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer","volume":"64","author":"Curiel","year":"2004","journal-title":"Cancer Res"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/nm1097","article-title":"Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of vegf-a","volume":"10","author":"Conejo-Garcia","year":"2004","journal-title":"Nat Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1096\/fj.09-147025","article-title":"Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells","volume":"24","author":"Fainaru","year":"2010","journal-title":"FASEB J"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00424","article-title":"Are mast cells masters in cancer","volume":"8","author":"Varricchi","year":"2017","journal-title":"Front Immunol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00131","article-title":"Orchestration of angiogenesis by immune cells","volume":"4","author":"Bruno","year":"2014","journal-title":"Front Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/142359","article-title":"The role of mast cell specific chymases and tryptases in tumor angiogenesis","volume":"2015","author":"de Souza Junior","year":"2015","journal-title":"BioMed Res Int"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.442","article-title":"Infiltrating mast cells promote renal cell carcinoma angiogenesis by modulating Pi3k\u2013>Akt\u2013>Gsk3beta\u2013>Am signaling","volume":"36","author":"Chen","year":"2017","journal-title":"Oncogene"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064159","article-title":"B cells promote tumor progression Via Stat3 regulated-angiogenesis","volume":"8","author":"Yang","year":"2013","journal-title":"PloS One"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.12.019","article-title":"Fcrgamma activation regulates inflammation-associated squamous carcinogenesis","volume":"17","author":"Andreu","year":"2010","journal-title":"Cancer Cell"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-015-9470-9","article-title":"An immature b cell population from peripheral blood serves as surrogate marker for monitoring tumor angiogenesis and anti-angiogenic therapy in mouse models","volume":"18","author":"Fagiani","year":"2015","journal-title":"Angiogenesis"},{"key":"B130","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2009.06.018","article-title":"Cd4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages","volume":"16","author":"DeNardo","year":"2009","journal-title":"Cancer Cell"},{"key":"B131","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/ncb3371","article-title":"Suppression of microrna activity amplifies ifn-Gamma-Induced macrophage activation and promotes anti-tumour immunity","volume":"18","author":"Baer","year":"2016","journal-title":"Nat Cell Biol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3892\/or.2011.1201","article-title":"Tumor-infiltrating Cd4+ Th17 cells produce il-17 in tumor microenvironment and promote tumor progression in human gastric cancer","volume":"25","author":"Iida","year":"2011","journal-title":"Oncol Rep"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2011.03.021","article-title":"Il-17 is associated with poor prognosis and promotes angiogenesis Via stimulating vegf production of cancer cells in colorectal carcinoma","volume":"407","author":"Liu","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/362841a0","article-title":"Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo","volume":"362","author":"Kim","year":"1993","journal-title":"Nature"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.671.65.3","article-title":"Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies","volume":"65","author":"Gerber","year":"2005","journal-title":"Cancer Res"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin(R)) in cancer treatment: A review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.10.017","article-title":"Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer","volume":"23","author":"Hurwitz","year":"2005","journal-title":"J Clin Oncol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102202","article-title":"Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase iii studies","volume":"97","author":"Salvatore","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B140","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.06.035","article-title":"Tumor vessel normalization by the Pi3k inhibitor hs-173 enhances drug delivery","volume":"403","author":"Kim","year":"2017","journal-title":"Cancer Lett"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-020518-114700","article-title":"Normalizing function of tumor vessels: Progress, opportunities, and challenges","volume":"81","author":"Martin","year":"2019","journal-title":"Annu Rev Physiol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1518808112","article-title":"Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients","volume":"112","author":"Tolaney","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B144","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12916-020-01610-0","article-title":"Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma","volume":"18","author":"Garcia-Romero","year":"2020","journal-title":"BMC Med"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1172\/JCI25705","article-title":"Pericytes limit tumor cell metastasis","volume":"116","author":"Xian","year":"2006","journal-title":"J Clin Invest"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2021.07.003","article-title":"Interplay between brain pericytes and endothelial cells in dementia","volume":"191","author":"Procter","year":"2021","journal-title":"Am J Pathol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2012.1366","article-title":"Medi3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models","volume":"40","author":"Leow","year":"2012","journal-title":"Int J Oncol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0213","article-title":"Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: Implications for amg 386, an angiopoietin-1\/2-Neutralizing peptibody","volume":"9","author":"Coxon","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.10.018","article-title":"Normalization of tumor vessels by Tie2 activation and Ang2 inhibition enhances drug delivery and produces a favorable tumor microenvironment","volume":"30","author":"Park","year":"2016","journal-title":"Cancer Cell"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1525360113","article-title":"Ang-2\/Vegf bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival","volume":"113","author":"Kloepper","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt164","article-title":"Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression","volume":"105","author":"Goel","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20150718","article-title":"Interfering with ve-ptp stabilizes endothelial junctions in vivo Via tie-2 in the absence of ve-cadherin","volume":"212","author":"Frye","year":"2015","journal-title":"J Exp Med"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1172\/JCI17929","article-title":"Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors","volume":"111","author":"Bergers","year":"2003","journal-title":"J Clin Invest"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1096\/fj.03-0271fje","article-title":"Combined inhibition of vegf and pdgf signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms","volume":"18","author":"Erber","year":"2004","journal-title":"FASEB J"},{"key":"B157","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4049\/jimmunol.172.1.7","article-title":"Regulation of leukocyte transmigration: Cell surface interactions and signaling events","volume":"172","author":"Liu","year":"2004","journal-title":"J Immunol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.5414\/cpp46236","article-title":"A phase I study of Cr002, a fully-human monoclonal antibody against platelet-derived growth factor-d","volume":"46","author":"Hawthorne","year":"2008","journal-title":"Int J Clin Pharmacol Ther"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.032","article-title":"Blockade of platelet-derived growth factor receptor-beta by Cdp860, a humanized, pegylated di-fab', leads to fluid accumulation and is associated with increased tumor vascularized volume","volume":"23","author":"Jayson","year":"2005","journal-title":"J Clin Oncol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-4245","article-title":"The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-a blockade","volume":"70","author":"Nisancioglu","year":"2010","journal-title":"Cancer Res"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31334","article-title":"Overexpression of pdgf-bb decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content","volume":"117","author":"McCarty","year":"2007","journal-title":"J Clin Invest"},{"key":"B162","doi-asserted-by":"publisher","first-page":"6011","DOI":"10.1038\/s41467-021-26259-y","article-title":"Hexokinase 2-driven glycolysis in pericytes activates their contractility leading to tumor blood vessel abnormalities","volume":"12","author":"Meng","year":"2021","journal-title":"Nat Commun"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201900153R","article-title":"Regulator of G-protein signaling 5 regulates the shift from perivascular to parenchymal pericytes in the chronic phase after stroke","volume":"33","author":"Roth","year":"2019","journal-title":"FASEB J"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-16908-4_4","article-title":"Pericytes in sarcomas and other mesenchymal tumors","volume":"1147","author":"Chang","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.687563","article-title":"Ve-cadherin and vesicles differentially regulate lymphatic vascular permeability to solutes of various sizes","volume":"12","author":"Jannaway","year":"2021","journal-title":"Front Physiol"},{"key":"B166","doi-asserted-by":"publisher","first-page":"e201909081","DOI":"10.1083\/jcb.201909081","article-title":"Ve-cadherin endocytosis controls vascular integrity and patterning during development","volume":"219","author":"Grimsley-Myers","year":"2020","journal-title":"J Cell Biol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2013.04.104","article-title":"Sac-1004, a novel vascular leakage blocker, enhances endothelial barrier through the Camp\/Rac\/Cortactin pathway","volume":"435","author":"Maharjan","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"B168","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2020.09.026","article-title":"The ve-Cadherin\/Beta-Catenin signalling axis regulates immune cell infiltration into tumours","volume":"496","author":"Zhao","year":"2021","journal-title":"Cancer Lett"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-016-2444-2","article-title":"Reverse transendothelial cell migration in inflammation: To help or to hinder","volume":"74","author":"Burn","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-499228","article-title":"How T cells trigger the dissociation of the endothelial receptor phosphatase ve-ptp from ve-cadherin","volume":"122","author":"Vockel","year":"2013","journal-title":"Blood"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.7150\/thno.22222","article-title":"Desacetylvinblastine monohydrazide disrupts tumor vessels by promoting ve-cadherin internalization","volume":"8","author":"Lei","year":"2018","journal-title":"Theranostics"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-3129","article-title":"Targeting vascular endothelial-cadherin in tumor-associated blood vessels promotes T-Cell-Mediated immunotherapy","volume":"77","author":"Zhao","year":"2017","journal-title":"Cancer Res"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4770-4","article-title":"Therapeutic regulation of ve-cadherin with a novel oligonucleotide drug for diabetic eye complications using retinopathy mouse models","volume":"62","author":"Ting","year":"2019","journal-title":"Diabetologia"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106333","article-title":"Pharmacological manipulation of Ezh2 with salvianolic acid b results in tumor vascular normalization and synergizes with cisplatin and T cell-mediated immunotherapy","volume":"182","author":"Qian","year":"2022","journal-title":"Pharmacol Res"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12814","article-title":"Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect","volume":"7","author":"Kleibeuker","year":"2016","journal-title":"Oncotarget"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.9b08460","article-title":"Gold nanoparticles induce tumor vessel normalization and impair metastasis by inhibiting endothelial Smad2\/3 signaling","volume":"14","author":"Huang","year":"2020","journal-title":"ACS Nano"},{"key":"B177","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ccr.2014.06.025","article-title":"Tumor vessel normalization by chloroquine independent of autophagy","volume":"26","author":"Maes","year":"2014","journal-title":"Cancer Cell"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.01.020","article-title":"Heterozygous deficiency of Phd2 restores tumor oxygenation and inhibits metastasis Via endothelial normalization","volume":"136","author":"Mazzone","year":"2009","journal-title":"Cell"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.119.316071","article-title":"B55alpha\/Pp2a limits endothelial cell apoptosis during vascular remodeling: A complementary approach to disrupt pathological vessels","volume":"127","author":"Ehling","year":"2020","journal-title":"Circ Res"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1038\/nature21724","article-title":"Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming","volume":"544","author":"Tian","year":"2017","journal-title":"Nature"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96582","article-title":"Increased vessel perfusion predicts the efficacy of immune checkpoint blockade","volume":"128","author":"Zheng","year":"2018","journal-title":"J Clin Invest"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32829","article-title":"Ctla4 blockade promotes vessel normalization in breast tumors Via the accumulation of eosinophils","volume":"146","author":"Zheng","year":"2020","journal-title":"Int J Cancer"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1118296109","article-title":"Tumor-targeted tnfalpha stabilizes tumor vessels and enhances active immunotherapy","volume":"109","author":"Johansson","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30889","article-title":"Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma","volume":"71","author":"Shigeta","year":"2020","journal-title":"Hepatology"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1172\/JCI125413","article-title":"Sting activation reprograms tumor vasculatures and synergizes with Vegfr2 blockade","volume":"129","author":"Yang","year":"2019","journal-title":"J Clin Invest"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.12.010","article-title":"Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation","volume":"76","author":"McGee","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2018.08.001","article-title":"Immunomodulation of tumor vessels: It takes two to tango","volume":"39","author":"Johansson-Percival","year":"2018","journal-title":"Trends Immunol"},{"key":"B188","doi-asserted-by":"publisher","first-page":"e2020057118","DOI":"10.1073\/pnas.2020057118","article-title":"Dll1 orchestrates Cd8(+) T cells to induce long-term vascular normalization and tumor regression","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2017.30","article-title":"Tumour vessel normalization and immune checkpoint blockade: A new synergism","volume":"95","author":"Ganss","year":"2017","journal-title":"Immunol Cell Biol"},{"key":"B190","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1568009619666191114110359","article-title":"Anti-Vegf\/Vegfr2 monoclonal antibodies and their combinations with pd-1\/Pd-L1 inhibitors in clinic","volume":"20","author":"Gao","year":"2020","journal-title":"Curr Cancer Drug Targets"},{"key":"B191","doi-asserted-by":"publisher","first-page":"eaak9670","DOI":"10.1126\/scitranslmed.aak9670","article-title":"Dual angiopoietin-2 and vegfa inhibition elicits antitumor immunity that is enhanced by pd-1 checkpoint blockade","volume":"9","author":"Schmittnaegel","year":"2017","journal-title":"Sci Transl Med"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2179","article-title":"Low-dose anti-angiogenic therapy sensitizes breast cancer to pd-1 blockade","volume":"26","author":"Li","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12069","article-title":"Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (Vegfr2) induces synergistic anti-tumour effect in vivo","volume":"172","author":"Yasuda","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20140559","article-title":"Vegf-a modulates expression of inhibitory checkpoints on Cd8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J Exp Med"},{"key":"B195","doi-asserted-by":"publisher","first-page":"eaak9679","DOI":"10.1126\/scitranslmed.aak9679","article-title":"Combined antiangiogenic and anti-Pd-L1 therapy stimulates tumor immunity through hev formation","volume":"9","author":"Allen","year":"2017","journal-title":"Sci Transl Med"},{"key":"B196","doi-asserted-by":"publisher","first-page":"eabc8922","DOI":"10.1126\/scitranslmed.abc8922","article-title":"Blockade of the Cd93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy","volume":"13","author":"Sun","year":"2021","journal-title":"Sci Transl Med"},{"key":"B197","doi-asserted-by":"publisher","first-page":"6988","DOI":"10.1158\/0008-5472.CAN-16-0888","article-title":"Efficacy of cotargeting angiopoietin-2 and the vegf pathway in the adjuvant postsurgical setting for early breast, colorectal, and renal cancers","volume":"76","author":"Wu","year":"2016","journal-title":"Cancer Res"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.736670","article-title":"High endothelial venules: A vascular perspective on tertiary lymphoid structures in cancer","volume":"12","author":"Vella","year":"2021","journal-title":"Front Immunol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2022.07.002","article-title":"High endothelial venules as potential gateways for therapeutics","volume":"43","author":"Hussain","year":"2022","journal-title":"Trends Immunol"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2176","article-title":"Combined vegf and pd-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer","volume":"78","author":"Meder","year":"2018","journal-title":"Cancer Res"},{"key":"B201","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1158\/2326-6066.CIR-16-0206","article-title":"Angiopoietin-2 as a biomarker and target for immune checkpoint therapy","volume":"5","author":"Wu","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1172\/JCI68897","article-title":"Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy","volume":"124","author":"D'Amico","year":"2014","journal-title":"J Clin Invest"},{"key":"B203","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.celrep.2014.06.059","article-title":"Role of angiopoietin-2 in adaptive tumor resistance to vegf signaling blockade","volume":"8","author":"Rigamonti","year":"2014","journal-title":"Cell Rep"},{"key":"B204","doi-asserted-by":"publisher","first-page":"eaay0555","DOI":"10.1126\/sciimmunol.aay0555","article-title":"Vegf-a drives tox-dependent T cell exhaustion in anti-Pd-1-Resistant microsatellite stable colorectal cancers","volume":"4","author":"Kim","year":"2019","journal-title":"Sci Immunol"},{"key":"B205","doi-asserted-by":"publisher","first-page":":e001126","DOI":"10.1136\/jitc-2020-001126","article-title":"Phase ii study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer","volume":"8","author":"Friedman","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30156-X","article-title":"Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (Go30140): An open-label, multicentre, phase 1b study","volume":"21","author":"Lee","year":"2020","journal-title":"Lancet Oncol"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30107-4","article-title":"Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (Javelin renal 100): An open-label, dose-finding and dose-expansion, phase 1b trial","volume":"19","author":"Choueiri","year":"2018","journal-title":"Lancet Oncol"},{"key":"B209","doi-asserted-by":"publisher","first-page":"e306\u201312","DOI":"10.1016\/j.clgc.2021.03.019","article-title":"Time to resolution of axitinib-related adverse events after treatment interruption in patients with advanced renal cell carcinoma","volume":"19","author":"Rini","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1044-8","article-title":"Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: Biomarker analysis of the phase 3 javelin renal 101 trial","volume":"26","author":"Motzer","year":"2020","journal-title":"Nat Med"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.010","article-title":"Updated efficacy results from the javelin renal 101 trial: First-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","volume":"31","author":"Choueiri","year":"2020","journal-title":"Ann Oncol"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.3171\/2016.8.PEDS16326","article-title":"Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: Case report","volume":"19","author":"Zhu","year":"2017","journal-title":"J Neurosurg Pediatr"},{"key":"B214","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","article-title":"Azd2171, a pan-vegf receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients","volume":"11","author":"Batchelor","year":"2007","journal-title":"Cancer Cell"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.9356","article-title":"Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice","volume":"27","author":"Kamoun","year":"2009","journal-title":"J Clin Oncol"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-Pd-1 and anti-Pd-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.2217\/nnm.13.106","article-title":"Nanotechnological strategies for therapeutic targeting of tumor vasculature","volume":"8","author":"Ding","year":"2013","journal-title":"Nanomedicine (Lond)"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2013.12.037","article-title":"Self-assembled peptide nanoparticles as tumor microenvironment activatable probes for tumor targeting and imaging","volume":"177","author":"Zhao","year":"2014","journal-title":"J Control Release"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1021\/acs.accounts.9b00283","article-title":"Smart nanotherapeutic targeting of tumor vasculature","volume":"52","author":"Li","year":"2019","journal-title":"Acc Chem Res"},{"key":"B222","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccell.2019.12.001","article-title":"An integrated gene expression landscape profiling approach to identify lung tumor endothelial cell heterogeneity and angiogenic candidates","volume":"37","author":"Goveia","year":"2020","journal-title":"Cancer Cell"},{"key":"B223","article-title":"Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy","volume":"63","author":"Pastorino","year":"2003","journal-title":"Cancer Res"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1126\/science.279.5349.377","article-title":"Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model","volume":"279","author":"Arap","year":"1998","journal-title":"Science"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12183","article-title":"Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges","volume":"41","author":"Li","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32201","article-title":"Immunovascular classification of hcc reflects reciprocal interaction between immune and angiogenic tumor microenvironments","volume":"75","author":"Kurebayashi","year":"2022","journal-title":"Hepatology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1035323\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T06:11:52Z","timestamp":1668060712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1035323\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":226,"alternative-id":["10.3389\/fimmu.2022.1035323"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1035323","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,10]]},"article-number":"1035323"}}